Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Post by cleareyeon Nov 14, 2023 1:42am
341 Views
Post# 35733567

High volume at support

High volume at supportThe share price hit a high of around 2.20 last July 4th, and then bounced off support at a low of 1.78 for a few days before beginning a journey to over 3.00.

Now, we're back at that support of 1.78, showing high volume as sellers have shown up. November tends to bring out the sellers after quarterly earnings reports.

This company is really showing promise with positive increases in key measures on the Income Statement. The Balance Sheet is being realistically cleaned up. The float is very low.

We'll see if the $1.78 level holds.

Bouncing from here would be a very good sign.

cleareye.
<< Previous
Bullboard Posts
Next >>